Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO...
LOS ANGELES--(BUSINESS WIRE)--Jun 2, 2019--
LOS ANGELES--(BUSINESS WIRE)--Jun 2, 2019--